Stem definition | Drug id | CAS RN |
---|---|---|
substances of the imipramine group | 701 | 303-49-1 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
0.10 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 13.24 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 51 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 13 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 8.20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.03 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 26 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 29, 1989 | FDA | MALLINCKRODT LLC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coma | 202.70 | 16.97 | 133 | 10277 | 56746 | 50537968 |
Intentional overdose | 179.65 | 16.97 | 128 | 10282 | 62376 | 50532338 |
Serotonin syndrome | 174.07 | 16.97 | 90 | 10320 | 24623 | 50570091 |
Drug interaction | 146.30 | 16.97 | 192 | 10218 | 199429 | 50395285 |
Overdose | 118.32 | 16.97 | 123 | 10287 | 99604 | 50495110 |
Bezoar | 115.54 | 16.97 | 31 | 10379 | 1317 | 50593397 |
Suicide attempt | 108.83 | 16.97 | 88 | 10322 | 51644 | 50543070 |
Poisoning deliberate | 99.50 | 16.97 | 43 | 10367 | 7869 | 50586845 |
Intentional self-injury | 94.49 | 16.97 | 59 | 10351 | 23053 | 50571661 |
Depressed level of consciousness | 87.94 | 16.97 | 78 | 10332 | 51875 | 50542839 |
Toxicity to various agents | 86.79 | 16.97 | 156 | 10254 | 212343 | 50382371 |
Antipsychotic drug level increased | 82.29 | 16.97 | 29 | 10381 | 3080 | 50591634 |
Neuroleptic malignant syndrome | 71.10 | 16.97 | 38 | 10372 | 11092 | 50583622 |
Sopor | 67.09 | 16.97 | 45 | 10365 | 19834 | 50574880 |
Tachycardia | 63.80 | 16.97 | 90 | 10320 | 99673 | 50495041 |
Antidepressant drug level increased | 58.43 | 16.97 | 13 | 10397 | 248 | 50594466 |
Electrocardiogram QT prolonged | 57.88 | 16.97 | 62 | 10348 | 51824 | 50542890 |
Pain | 52.43 | 16.97 | 27 | 10383 | 578876 | 50015838 |
Hypertonia | 51.28 | 16.97 | 22 | 10388 | 3951 | 50590763 |
Cerebellar syndrome | 48.29 | 16.97 | 20 | 10390 | 3291 | 50591423 |
Myoclonus | 47.02 | 16.97 | 32 | 10378 | 14438 | 50580276 |
Tremor | 46.33 | 16.97 | 84 | 10326 | 114819 | 50479895 |
Sinus tachycardia | 44.17 | 16.97 | 36 | 10374 | 21318 | 50573396 |
Agitation | 43.08 | 16.97 | 54 | 10356 | 53330 | 50541384 |
Somnolence | 43.02 | 16.97 | 97 | 10313 | 154888 | 50439826 |
Confusional state | 42.59 | 16.97 | 108 | 10302 | 185820 | 50408894 |
Livedo reticularis | 41.71 | 16.97 | 16 | 10394 | 2156 | 50592558 |
Suicidal ideation | 41.50 | 16.97 | 54 | 10356 | 55331 | 50539383 |
Akathisia | 41.36 | 16.97 | 24 | 10386 | 8205 | 50586509 |
Altered state of consciousness | 41.29 | 16.97 | 35 | 10375 | 21875 | 50572839 |
International normalised ratio abnormal | 40.88 | 16.97 | 17 | 10393 | 2826 | 50591888 |
Psychomotor hyperactivity | 38.64 | 16.97 | 24 | 10386 | 9277 | 50585437 |
Ventricular dyskinesia | 37.52 | 16.97 | 8 | 10402 | 124 | 50594590 |
Hyposmia | 36.83 | 16.97 | 10 | 10400 | 444 | 50594270 |
Hyperchloraemia | 36.83 | 16.97 | 11 | 10399 | 690 | 50594024 |
Drug abuse | 36.76 | 16.97 | 53 | 10357 | 59793 | 50534921 |
Joint swelling | 34.00 | 16.97 | 5 | 10405 | 245281 | 50349433 |
Pneumonia aspiration | 32.73 | 16.97 | 36 | 10374 | 30968 | 50563746 |
Poisoning | 32.32 | 16.97 | 24 | 10386 | 12405 | 50582309 |
Urinary retention | 32.23 | 16.97 | 33 | 10377 | 26157 | 50568557 |
Hypotension | 32.22 | 16.97 | 114 | 10296 | 235355 | 50359359 |
Hypotonia | 31.31 | 16.97 | 20 | 10390 | 8114 | 50586600 |
Newborn persistent pulmonary hypertension | 31.00 | 16.97 | 7 | 10403 | 143 | 50594571 |
Arthralgia | 30.86 | 16.97 | 27 | 10383 | 438675 | 50156039 |
Cor pulmonale acute | 30.23 | 16.97 | 8 | 10402 | 322 | 50594392 |
Drug withdrawal syndrome neonatal | 29.86 | 16.97 | 12 | 10398 | 1829 | 50592885 |
Hyperthermia | 29.81 | 16.97 | 19 | 10391 | 7677 | 50587037 |
Parkinsonism | 29.78 | 16.97 | 20 | 10390 | 8827 | 50585887 |
Alopecia | 29.68 | 16.97 | 7 | 10403 | 245040 | 50349674 |
Mental disorder | 29.43 | 16.97 | 29 | 10381 | 21962 | 50572752 |
Disturbance in attention | 29.15 | 16.97 | 34 | 10376 | 31152 | 50563562 |
Diarrhoea | 28.91 | 16.97 | 48 | 10362 | 588428 | 50006286 |
Post-anoxic myoclonus | 28.66 | 16.97 | 5 | 10405 | 24 | 50594690 |
Polyuria | 28.63 | 16.97 | 18 | 10392 | 7103 | 50587611 |
Miosis | 28.04 | 16.97 | 17 | 10393 | 6293 | 50588421 |
Drug level increased | 26.89 | 16.97 | 26 | 10384 | 19242 | 50575472 |
Fatigue | 26.88 | 16.97 | 67 | 10343 | 707534 | 49887180 |
Inappropriate antidiuretic hormone secretion | 26.84 | 16.97 | 22 | 10388 | 13121 | 50581593 |
Blood prolactin increased | 26.84 | 16.97 | 13 | 10397 | 3086 | 50591628 |
Urine osmolarity increased | 26.70 | 16.97 | 6 | 10404 | 120 | 50594594 |
Hallucination, auditory | 26.31 | 16.97 | 20 | 10390 | 10708 | 50584006 |
Psychomotor retardation | 25.63 | 16.97 | 13 | 10397 | 3405 | 50591309 |
Retroplacental haematoma | 25.54 | 16.97 | 6 | 10404 | 147 | 50594567 |
Psychomotor skills impaired | 25.23 | 16.97 | 11 | 10399 | 2053 | 50592661 |
Circulatory collapse | 24.25 | 16.97 | 25 | 10385 | 19975 | 50574739 |
Cyanosis | 24.09 | 16.97 | 22 | 10388 | 15162 | 50579552 |
Mania | 23.83 | 16.97 | 19 | 10391 | 10897 | 50583817 |
Hepatocellular injury | 23.77 | 16.97 | 28 | 10382 | 25919 | 50568795 |
Shock | 23.58 | 16.97 | 25 | 10385 | 20625 | 50574089 |
Muscle rigidity | 23.39 | 16.97 | 18 | 10392 | 9811 | 50584903 |
Spasmodic dysphonia | 23.36 | 16.97 | 5 | 10405 | 79 | 50594635 |
Otorrhoea | 23.22 | 16.97 | 9 | 10401 | 1247 | 50593467 |
Hypokalaemia | 23.19 | 16.97 | 54 | 10356 | 87938 | 50506776 |
Obsessive-compulsive disorder | 23.02 | 16.97 | 12 | 10398 | 3328 | 50591386 |
Restlessness | 22.79 | 16.97 | 27 | 10383 | 25146 | 50569568 |
Product dose omission issue | 22.75 | 16.97 | 5 | 10405 | 183833 | 50410881 |
Electrocardiogram QRS complex prolonged | 22.73 | 16.97 | 14 | 10396 | 5330 | 50589384 |
Lactic acidosis | 22.64 | 16.97 | 31 | 10379 | 33324 | 50561390 |
Asphyxia | 22.53 | 16.97 | 14 | 10396 | 5413 | 50589301 |
Nephrogenic diabetes insipidus | 22.48 | 16.97 | 8 | 10402 | 873 | 50593841 |
Right ventricular dilatation | 21.85 | 16.97 | 8 | 10402 | 948 | 50593766 |
Rash | 21.15 | 16.97 | 36 | 10374 | 437435 | 50157279 |
Hyponatraemia | 21.09 | 16.97 | 55 | 10355 | 96084 | 50498630 |
Foetal arrhythmia | 21.03 | 16.97 | 5 | 10405 | 129 | 50594585 |
Contraindicated product administered | 20.71 | 16.97 | 3 | 10407 | 148955 | 50445759 |
Nasopharyngitis | 20.59 | 16.97 | 7 | 10403 | 192920 | 50401794 |
Mydriasis | 20.07 | 16.97 | 17 | 10393 | 10610 | 50584104 |
Onychophagia | 19.71 | 16.97 | 4 | 10406 | 48 | 50594666 |
Peripheral swelling | 19.48 | 16.97 | 9 | 10401 | 205927 | 50388787 |
Hyperhidrosis | 19.45 | 16.97 | 51 | 10359 | 89375 | 50505339 |
Drug hypersensitivity | 19.43 | 16.97 | 14 | 10396 | 250996 | 50343718 |
Cholestasis | 19.38 | 16.97 | 25 | 10385 | 25376 | 50569338 |
Drug screen false positive | 19.26 | 16.97 | 7 | 10403 | 812 | 50593902 |
Rheumatoid arthritis | 18.93 | 16.97 | 9 | 10401 | 202541 | 50392173 |
Tardive dyskinesia | 18.80 | 16.97 | 14 | 10396 | 7265 | 50587449 |
Treatment failure | 18.61 | 16.97 | 3 | 10407 | 137634 | 50457080 |
Acquired haemophilia | 18.59 | 16.97 | 7 | 10403 | 896 | 50593818 |
Apathy | 18.35 | 16.97 | 14 | 10396 | 7534 | 50587180 |
Therapeutic product effect decreased | 18.32 | 16.97 | 3 | 10407 | 136047 | 50458667 |
Respiratory depression | 18.27 | 16.97 | 17 | 10393 | 11993 | 50582721 |
Hyporesponsive to stimuli | 18.23 | 16.97 | 7 | 10403 | 945 | 50593769 |
Morbid thoughts | 18.03 | 16.97 | 6 | 10404 | 536 | 50594178 |
Headache | 17.63 | 16.97 | 50 | 10360 | 506485 | 50088229 |
Rhabdomyolysis | 17.60 | 16.97 | 30 | 10380 | 38997 | 50555717 |
Loss of consciousness | 17.33 | 16.97 | 54 | 10356 | 104299 | 50490415 |
Toxic skin eruption | 17.26 | 16.97 | 16 | 10394 | 11235 | 50583479 |
Infection | 17.24 | 16.97 | 7 | 10403 | 172947 | 50421767 |
Swelling | 17.18 | 16.97 | 10 | 10400 | 200862 | 50393852 |
Anticholinergic syndrome | 16.98 | 16.97 | 8 | 10402 | 1787 | 50592927 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Suicide attempt | 262.56 | 21.69 | 141 | 7349 | 33969 | 29533068 |
Therapeutic product effect variable | 250.51 | 21.69 | 64 | 7426 | 1813 | 29565224 |
Obsessive-compulsive disorder | 247.66 | 21.69 | 77 | 7413 | 4499 | 29562538 |
Antipsychotic drug level below therapeutic | 242.46 | 21.69 | 63 | 7427 | 1911 | 29565126 |
Disinhibition | 229.67 | 21.69 | 64 | 7426 | 2543 | 29564494 |
Euphoric mood | 210.85 | 21.69 | 69 | 7421 | 4756 | 29562281 |
Akathisia | 199.44 | 21.69 | 72 | 7418 | 6670 | 29560367 |
Increased appetite | 180.25 | 21.69 | 65 | 7425 | 5999 | 29561038 |
Toxicity to various agents | 118.89 | 21.69 | 180 | 7310 | 173481 | 29393556 |
Serotonin syndrome | 100.93 | 21.69 | 60 | 7430 | 17452 | 29549585 |
Intentional overdose | 100.53 | 21.69 | 81 | 7409 | 38447 | 29528590 |
Coma | 88.49 | 21.69 | 76 | 7414 | 39374 | 29527663 |
Poisoning deliberate | 84.36 | 21.69 | 37 | 7453 | 5694 | 29561343 |
Dyslipidaemia | 82.37 | 21.69 | 37 | 7453 | 6024 | 29561013 |
Neuroleptic malignant syndrome | 76.91 | 21.69 | 49 | 7441 | 16099 | 29550938 |
Obesity | 76.32 | 21.69 | 41 | 7449 | 9822 | 29557215 |
Therapeutic product effect incomplete | 72.84 | 21.69 | 68 | 7422 | 39237 | 29527800 |
Leukaemia | 70.71 | 21.69 | 29 | 7461 | 3781 | 29563256 |
Prescribed overdose | 69.73 | 21.69 | 37 | 7453 | 8646 | 29558391 |
Electrocardiogram QT prolonged | 67.88 | 21.69 | 63 | 7427 | 36074 | 29530963 |
Weight increased | 66.25 | 21.69 | 89 | 7401 | 76578 | 29490459 |
Sopor | 64.38 | 21.69 | 38 | 7452 | 10896 | 29556141 |
Leukopenia | 61.87 | 21.69 | 73 | 7417 | 55130 | 29511907 |
Extrapyramidal disorder | 54.40 | 21.69 | 34 | 7456 | 10797 | 29556240 |
Intentional self-injury | 52.44 | 21.69 | 35 | 7455 | 12426 | 29554611 |
Agitation | 48.04 | 21.69 | 62 | 7428 | 51242 | 29515795 |
Somnolence | 44.73 | 21.69 | 83 | 7407 | 93872 | 29473165 |
Compartment syndrome | 43.24 | 21.69 | 18 | 7472 | 2434 | 29564603 |
Schizoaffective disorder | 41.23 | 21.69 | 14 | 7476 | 1078 | 29565959 |
Overdose | 41.14 | 21.69 | 73 | 7417 | 79746 | 29487291 |
Renal hypertension | 38.97 | 21.69 | 9 | 7481 | 164 | 29566873 |
Drug interaction | 36.29 | 21.69 | 121 | 7369 | 197264 | 29369773 |
Loose associations | 35.72 | 21.69 | 7 | 7483 | 55 | 29566982 |
Brachial plexus injury | 33.85 | 21.69 | 7 | 7483 | 74 | 29566963 |
Tremor | 30.12 | 21.69 | 61 | 7429 | 73477 | 29493560 |
Hypothermia | 29.67 | 21.69 | 22 | 7468 | 9217 | 29557820 |
Rhabdomyolysis | 29.25 | 21.69 | 54 | 7436 | 60754 | 29506283 |
Fatigue | 28.72 | 21.69 | 23 | 7467 | 316798 | 29250239 |
Mania | 28.65 | 21.69 | 21 | 7469 | 8642 | 29558395 |
Hypertonia neonatal | 27.06 | 21.69 | 8 | 7482 | 392 | 29566645 |
Aggression | 25.79 | 21.69 | 38 | 7452 | 35503 | 29531534 |
Coma scale abnormal | 25.65 | 21.69 | 14 | 7476 | 3455 | 29563582 |
Pneumonia | 23.50 | 21.69 | 28 | 7462 | 320144 | 29246893 |
Diarrhoea | 23.48 | 21.69 | 30 | 7460 | 332668 | 29234369 |
Bradykinesia | 22.99 | 21.69 | 13 | 7477 | 3434 | 29563603 |
Hyperthermia | 22.81 | 21.69 | 19 | 7471 | 9411 | 29557626 |
Dyspraxia | 22.74 | 21.69 | 7 | 7483 | 394 | 29566643 |
Drug withdrawal syndrome | 22.15 | 21.69 | 25 | 7465 | 17959 | 29549078 |
Cough | 22.04 | 21.69 | 3 | 7487 | 126724 | 29440313 |
Depressed level of consciousness | 21.91 | 21.69 | 36 | 7454 | 36906 | 29530131 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coma | 285.78 | 16.15 | 201 | 14375 | 87414 | 64396742 |
Serotonin syndrome | 255.61 | 16.15 | 140 | 14436 | 39142 | 64445014 |
Suicide attempt | 238.68 | 16.15 | 166 | 14410 | 70841 | 64413315 |
Intentional overdose | 229.42 | 16.15 | 178 | 14398 | 89766 | 64394390 |
Poisoning deliberate | 168.61 | 16.15 | 75 | 14501 | 13383 | 64470773 |
Neuroleptic malignant syndrome | 151.32 | 16.15 | 85 | 14491 | 24911 | 64459245 |
Drug interaction | 150.14 | 16.15 | 282 | 14294 | 361801 | 64122355 |
Overdose | 134.99 | 16.15 | 173 | 14403 | 159393 | 64324763 |
Sopor | 127.74 | 16.15 | 81 | 14495 | 29580 | 64454576 |
Toxicity to various agents | 127.49 | 16.15 | 264 | 14312 | 363249 | 64120907 |
Bezoar | 105.94 | 16.15 | 33 | 14543 | 2170 | 64481986 |
Electrocardiogram QT prolonged | 102.22 | 16.15 | 107 | 14469 | 79341 | 64404815 |
Intentional self-injury | 93.02 | 16.15 | 66 | 14510 | 28978 | 64455178 |
Akathisia | 85.95 | 16.15 | 45 | 14531 | 11465 | 64472691 |
Somnolence | 79.65 | 16.15 | 155 | 14421 | 203490 | 64280666 |
Depressed level of consciousness | 76.26 | 16.15 | 93 | 14483 | 81343 | 64402813 |
Obsessive-compulsive disorder | 73.94 | 16.15 | 31 | 14545 | 4787 | 64479369 |
Agitation | 68.68 | 16.15 | 92 | 14484 | 88275 | 64395881 |
Tremor | 60.57 | 16.15 | 115 | 14461 | 148115 | 64336041 |
Tachycardia | 59.83 | 16.15 | 115 | 14461 | 149464 | 64334692 |
Antidepressant drug level increased | 57.78 | 16.15 | 14 | 14562 | 356 | 64483800 |
Hyperthermia | 56.03 | 16.15 | 38 | 14538 | 15512 | 64468644 |
Pain | 54.02 | 16.15 | 29 | 14547 | 553482 | 63930674 |
Psychomotor hyperactivity | 53.70 | 16.15 | 36 | 14540 | 14415 | 64469741 |
Confusional state | 53.04 | 16.15 | 154 | 14422 | 260990 | 64223166 |
Antipsychotic drug level increased | 53.03 | 16.15 | 25 | 14551 | 5090 | 64479066 |
Mania | 52.11 | 16.15 | 37 | 14539 | 16249 | 64467907 |
Altered state of consciousness | 50.41 | 16.15 | 52 | 14524 | 37850 | 64446306 |
Rhabdomyolysis | 50.25 | 16.15 | 81 | 14495 | 91645 | 64392511 |
Suicidal ideation | 48.24 | 16.15 | 67 | 14509 | 66475 | 64417681 |
Parkinsonism | 46.79 | 16.15 | 33 | 14543 | 14340 | 64469816 |
Antipsychotic drug level below therapeutic | 44.21 | 16.15 | 14 | 14562 | 971 | 64483185 |
Extrapyramidal disorder | 43.97 | 16.15 | 36 | 14540 | 19516 | 64464640 |
Diarrhoea | 42.61 | 16.15 | 61 | 14515 | 722643 | 63761513 |
Myoclonus | 41.88 | 16.15 | 39 | 14537 | 25079 | 64459077 |
Cerebellar syndrome | 41.45 | 16.15 | 21 | 14555 | 4995 | 64479161 |
Pneumonia aspiration | 40.47 | 16.15 | 58 | 14518 | 59213 | 64424943 |
Fatigue | 39.57 | 16.15 | 68 | 14508 | 748662 | 63735494 |
Renal hypertension | 38.69 | 16.15 | 9 | 14567 | 191 | 64483965 |
Psychomotor retardation | 38.08 | 16.15 | 20 | 14556 | 5123 | 64479033 |
Arthralgia | 37.79 | 16.15 | 27 | 14549 | 442233 | 64041923 |
Hallucination, auditory | 37.69 | 16.15 | 31 | 14545 | 16908 | 64467248 |
Sinus tachycardia | 37.21 | 16.15 | 41 | 14535 | 32147 | 64452009 |
Therapeutic product effect variable | 37.19 | 16.15 | 14 | 14562 | 1630 | 64482526 |
Disinhibition | 36.33 | 16.15 | 15 | 14561 | 2228 | 64481928 |
Loose associations | 36.18 | 16.15 | 7 | 14569 | 58 | 64484098 |
Euphoric mood | 36.07 | 16.15 | 21 | 14555 | 6570 | 64477586 |
Compartment syndrome | 35.80 | 16.15 | 18 | 14558 | 4214 | 64479942 |
Peripheral swelling | 33.45 | 16.15 | 4 | 14572 | 209149 | 64275007 |
Hepatocellular injury | 33.45 | 16.15 | 46 | 14530 | 45189 | 64438967 |
Nasopharyngitis | 33.29 | 16.15 | 3 | 14573 | 196070 | 64288086 |
Prescribed overdose | 32.80 | 16.15 | 31 | 14545 | 20300 | 64463856 |
Apathy | 32.47 | 16.15 | 24 | 14552 | 11208 | 64472948 |
Joint swelling | 32.36 | 16.15 | 5 | 14571 | 215377 | 64268779 |
Hyperchloraemia | 32.20 | 16.15 | 11 | 14565 | 968 | 64483188 |
Livedo reticularis | 32.08 | 16.15 | 16 | 14560 | 3681 | 64480475 |
Brachial plexus injury | 32.08 | 16.15 | 7 | 14569 | 110 | 64484046 |
Urinary retention | 31.91 | 16.15 | 47 | 14529 | 49154 | 64435002 |
Hypertonia | 31.60 | 16.15 | 19 | 14557 | 6306 | 64477850 |
Shock | 31.51 | 16.15 | 41 | 14535 | 38199 | 64445957 |
Bronchial hyperreactivity | 31.45 | 16.15 | 14 | 14562 | 2498 | 64481658 |
Bradykinesia | 30.96 | 16.15 | 19 | 14557 | 6541 | 64477615 |
Muscle rigidity | 30.82 | 16.15 | 28 | 14548 | 17445 | 64466711 |
Schizoaffective disorder | 30.49 | 16.15 | 12 | 14564 | 1575 | 64482581 |
International normalised ratio abnormal | 30.26 | 16.15 | 17 | 14559 | 4971 | 64479185 |
Hyperhidrosis | 29.59 | 16.15 | 78 | 14498 | 124842 | 64359314 |
Electrocardiogram QRS complex prolonged | 29.57 | 16.15 | 21 | 14555 | 9223 | 64474933 |
Hyposmia | 29.32 | 16.15 | 9 | 14567 | 563 | 64483593 |
Miosis | 28.94 | 16.15 | 24 | 14552 | 13242 | 64470914 |
Drug abuse | 28.70 | 16.15 | 80 | 14496 | 132294 | 64351862 |
Pressure of speech | 28.12 | 16.15 | 10 | 14566 | 991 | 64483165 |
Post-anoxic myoclonus | 28.02 | 16.15 | 5 | 14571 | 25 | 64484131 |
Coma scale abnormal | 28.01 | 16.15 | 19 | 14557 | 7755 | 64476401 |
Polyuria | 27.84 | 16.15 | 23 | 14553 | 12620 | 64471536 |
Ventricular dyskinesia | 27.80 | 16.15 | 8 | 14568 | 400 | 64483756 |
Circulatory collapse | 27.54 | 16.15 | 36 | 14540 | 33696 | 64450460 |
Obesity | 26.95 | 16.15 | 28 | 14548 | 20534 | 64463622 |
Inappropriate antidiuretic hormone secretion | 26.82 | 16.15 | 29 | 14547 | 22260 | 64461896 |
Asphyxia | 26.67 | 16.15 | 20 | 14556 | 9546 | 64474610 |
Infusion related reaction | 26.66 | 16.15 | 3 | 14573 | 164464 | 64319692 |
Retroplacental haematoma | 26.42 | 16.15 | 6 | 14570 | 114 | 64484042 |
Breast disorder | 26.39 | 16.15 | 11 | 14565 | 1673 | 64482483 |
Disturbance in attention | 26.30 | 16.15 | 39 | 14537 | 41035 | 64443121 |
Mental disorder | 26.03 | 16.15 | 31 | 14545 | 26414 | 64457742 |
Intentional product misuse | 25.76 | 16.15 | 53 | 14523 | 72242 | 64411914 |
Rash | 25.69 | 16.15 | 40 | 14536 | 458509 | 64025647 |
Speech disorder | 25.45 | 16.15 | 42 | 14534 | 48399 | 64435757 |
Seizure | 25.22 | 16.15 | 89 | 14487 | 166803 | 64317353 |
Loss of consciousness | 24.94 | 16.15 | 82 | 14494 | 148283 | 64335873 |
Febrile neutropenia | 24.72 | 16.15 | 6 | 14570 | 187651 | 64296505 |
Cor pulmonale acute | 24.48 | 16.15 | 8 | 14568 | 614 | 64483542 |
Generalised tonic-clonic seizure | 24.31 | 16.15 | 37 | 14539 | 39820 | 64444336 |
Abdominal pain | 24.22 | 16.15 | 21 | 14555 | 312354 | 64171802 |
Hypothermia | 24.18 | 16.15 | 26 | 14550 | 19830 | 64464326 |
Drug level increased | 24.12 | 16.15 | 34 | 14542 | 34162 | 64449994 |
Blood prolactin increased | 24.09 | 16.15 | 13 | 14563 | 3515 | 64480641 |
Mydriasis | 24.04 | 16.15 | 23 | 14553 | 15289 | 64468867 |
Nausea | 24.03 | 16.15 | 94 | 14482 | 785706 | 63698450 |
Poisoning | 23.80 | 16.15 | 27 | 14549 | 21852 | 64462304 |
Psychomotor skills impaired | 23.05 | 16.15 | 13 | 14563 | 3832 | 64480324 |
Pneumonia | 22.64 | 16.15 | 59 | 14517 | 559517 | 63924639 |
Cough | 22.60 | 16.15 | 21 | 14555 | 302127 | 64182029 |
Product dose omission issue | 22.42 | 16.15 | 8 | 14568 | 194739 | 64289417 |
Hepatic cytolysis | 21.86 | 16.15 | 21 | 14555 | 14028 | 64470128 |
Restlessness | 21.58 | 16.15 | 35 | 14541 | 39750 | 64444406 |
Pain in extremity | 21.58 | 16.15 | 22 | 14554 | 303063 | 64181093 |
Urine osmolarity increased | 21.44 | 16.15 | 6 | 14570 | 271 | 64483885 |
Dyspraxia | 21.31 | 16.15 | 6 | 14570 | 277 | 64483879 |
Hypotension | 21.22 | 16.15 | 153 | 14423 | 380821 | 64103335 |
Anxiety | 20.94 | 16.15 | 96 | 14480 | 202553 | 64281603 |
Otorrhoea | 20.87 | 16.15 | 9 | 14567 | 1488 | 64482668 |
Hypokalaemia | 20.15 | 16.15 | 67 | 14509 | 121836 | 64362320 |
Pleurothotonus | 20.08 | 16.15 | 10 | 14566 | 2292 | 64481864 |
Product use in unapproved indication | 20.00 | 16.15 | 86 | 14490 | 176532 | 64307624 |
Clonus | 19.91 | 16.15 | 14 | 14562 | 6053 | 64478103 |
Morbid thoughts | 19.44 | 16.15 | 7 | 14569 | 719 | 64483437 |
Death | 19.43 | 16.15 | 51 | 14525 | 482654 | 64001502 |
Spasmodic dysphonia | 19.13 | 16.15 | 5 | 14571 | 174 | 64483982 |
Aggression | 19.01 | 16.15 | 36 | 14540 | 46196 | 64437960 |
Nephrogenic diabetes insipidus | 18.88 | 16.15 | 9 | 14567 | 1878 | 64482278 |
Anticholinergic syndrome | 18.69 | 16.15 | 10 | 14566 | 2659 | 64481497 |
Dyslipidaemia | 18.67 | 16.15 | 16 | 14560 | 9226 | 64474930 |
Sepsis | 18.44 | 16.15 | 15 | 14561 | 230326 | 64253830 |
Feelings of worthlessness | 18.11 | 16.15 | 6 | 14570 | 480 | 64483676 |
Sleep disorder | 18.09 | 16.15 | 41 | 14535 | 59668 | 64424488 |
Abulia | 18.04 | 16.15 | 7 | 14569 | 884 | 64483272 |
Right ventricular dilatation | 17.92 | 16.15 | 8 | 14568 | 1437 | 64482719 |
Hyperreflexia | 17.85 | 16.15 | 14 | 14562 | 7134 | 64477022 |
Stupor | 17.68 | 16.15 | 13 | 14563 | 6022 | 64478134 |
Headache | 17.68 | 16.15 | 61 | 14515 | 529406 | 63954750 |
Rebound effect | 17.67 | 16.15 | 12 | 14564 | 4905 | 64479251 |
Disorientation | 17.65 | 16.15 | 39 | 14537 | 55789 | 64428367 |
Blood creatine phosphokinase increased | 17.50 | 16.15 | 40 | 14536 | 58518 | 64425638 |
Hyponatraemia | 17.39 | 16.15 | 73 | 14503 | 148266 | 64335890 |
Increased appetite | 17.38 | 16.15 | 16 | 14560 | 10130 | 64474026 |
Drug screen false positive | 17.18 | 16.15 | 7 | 14569 | 1005 | 64483151 |
Alopecia | 17.13 | 16.15 | 8 | 14568 | 165682 | 64318474 |
Onychophagia | 17.06 | 16.15 | 4 | 14572 | 88 | 64484068 |
Irritability | 16.85 | 16.15 | 30 | 14546 | 36716 | 64447440 |
Hypernatraemia | 16.70 | 16.15 | 17 | 14559 | 12172 | 64471984 |
Therapeutic product effect decreased | 16.60 | 16.15 | 3 | 14573 | 115348 | 64368808 |
None
Source | Code | Description |
---|---|---|
ATC | N06AA04 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors |
CHEBI has role | CHEBI:35469 | antidepressants |
CHEBI has role | CHEBI:48278 | serotonergic drugs |
CHEBI has role | CHEBI:48279 | serotonin antagonists |
CHEBI has role | CHEBI:149553 | anticoronaviral drug |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D000929 | Antidepressive Agents, Tricyclic |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D017367 | Serotonin Uptake Inhibitors |
FDA EPC | N0000175752 | Tricyclic Antidepressant |
CHEBI has role | CHEBI:50949 | SSRI |
CHEBI has role | CHEBI:77402 | EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Obsessive-compulsive disorder | indication | 191736004 | DOID:10933 |
Depressive disorder | off-label use | 35489007 | |
Cataplexy | off-label use | 46263000 | |
Anxiety | off-label use | 48694002 | |
Panic disorder | off-label use | 371631005 | DOID:594 |
Suicidal thoughts | contraindication | 6471006 | |
Alcoholism | contraindication | 7200002 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Acute nephropathy | contraindication | 58574008 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Bipolar affective disorder, current episode manic | contraindication | 191618007 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Retention of urine | contraindication | 267064002 | |
Pheochromocytoma | contraindication | 302835009 | |
Malignant hyperthermia | contraindication | 405501007 | |
Myocardial infarction in recovery phase | contraindication | 418044006 | |
Neuroblastoma | contraindication | 432328008 | DOID:769 |
Atrioventricular Conduction Defect | contraindication |
Species | Use | Relation |
---|---|---|
Dogs | Separation anxiety | Indication |
Product | Applicant | Ingredients |
---|---|---|
Clomicalm Tablets | Virbac AH Inc. | 1 |
Clomipramine Hydrochloride Tablets | Mizner Bioscience LLC | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.04 | Basic |
pKa2 | 6.19 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | Kd | 7.42 | WOMBAT-PK | IUPHAR | |||
Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Ki | 9.70 | PDSP | CHEMBL | |||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.28 | PDSP | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.24 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 7.45 | PDSP | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.82 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.19 | PDSP | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.95 | CHEMBL | |||||
Alpha-1A adrenergic receptor | GPCR | Ki | 8.50 | WOMBAT-PK | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 7.34 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 7.41 | PDSP | |||||
Histamine H1 receptor | GPCR | Ki | 8.01 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.70 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.66 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.07 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.44 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.89 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.42 | DRUG MATRIX | |||||
Aldehyde oxidase | Enzyme | IC50 | 6.32 | WOMBAT-PK | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 6.69 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | IC50 | 5.56 | CHEMBL | |||||
Cytochrome P450 2D6 | Enzyme | Ki | 5.66 | WOMBAT-PK | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 7.40 | DRUG MATRIX | |||||
Glutathione S-transferase P | Enzyme | WOMBAT-PK | |||||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.71 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 6.66 | PDSP | |||||
D(2) dopamine receptor | GPCR | Ki | 6.95 | PDSP | |||||
Trypanothione reductase | Enzyme | Ki | 5.19 | CHEMBL | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 7.14 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 5.94 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 10.40 | CHEMBL | |||||
D(2) dopamine receptor | GPCR | Ki | 7.25 | CHEMBL | |||||
Sodium-dependent noradrenaline transporter | Transporter | IC50 | 6.05 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | IC50 | 7.15 | CHEMBL | |||||
Histamine H1 receptor | GPCR | IC50 | 9.70 | CHEMBL | |||||
Serotonin (5-HT) receptor | GPCR | IC50 | 8.30 | CHEMBL | |||||
Serotonin 1 (5-HT1) receptor | GPCR | Ki | 5.30 | CHEMBL | |||||
Adrenergic receptor alpha-2 | GPCR | Ki | 7.29 | CHEMBL | |||||
Serotonin 2 (5-HT2) receptor | GPCR | Ki | 8.08 | CHEMBL | |||||
Trypanothione reductase | Enzyme | IC50 | 5.47 | CHEMBL | |||||
G protein-activated inward rectifier potassium channel 2 | Ion channel | BLOCKER | IC50 | 4.40 | IUPHAR |
ID | Source |
---|---|
4019687 | VUID |
N0000147779 | NUI |
D00811 | KEGG_DRUG |
17321-77-6 | SECONDARY_CAS_RN |
2597 | RXNORM |
4019492 | VANDF |
4019687 | VANDF |
C0009010 | UMLSCUI |
CHEBI:47780 | CHEBI |
CXX | PDB_CHEM_ID |
CHEMBL415 | ChEMBL_ID |
CHEMBL1200710 | ChEMBL_ID |
DB01242 | DRUGBANK_ID |
D002997 | MESH_DESCRIPTOR_UI |
2801 | PUBCHEM_CID |
2398 | IUPHAR_LIGAND_ID |
2238 | INN_ID |
NUV44L116D | UNII |
373 | MMSL |
4476 | MMSL |
d00876 | MMSL |
003456 | NDDF |
004614 | NDDF |
372903001 | SNOMEDCT_US |
387027004 | SNOMEDCT_US |
96209002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3025 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3050 | CAPSULE | 50 mg | ORAL | ANDA | 25 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3075 | CAPSULE | 75 mg | ORAL | ANDA | 25 sections |
CLOMIPRAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0406-8806 | CAPSULE | 25 mg | ORAL | NDA | 24 sections |
CLOMIPRAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0406-8807 | CAPSULE | 50 mg | ORAL | NDA | 24 sections |
CLOMIPRAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0406-8808 | CAPSULE | 75 mg | ORAL | NDA | 24 sections |
ANAFRANIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0406-9906 | CAPSULE | 25 mg | ORAL | NDA | 24 sections |
ANAFRANIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0406-9907 | CAPSULE | 50 mg | ORAL | NDA | 24 sections |
ANAFRANIL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0406-9908 | CAPSULE | 75 mg | ORAL | NDA | 24 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-2027 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-2037 | CAPSULE | 50 mg | ORAL | ANDA | 25 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0630 | CAPSULE | 25 mg | ORAL | ANDA | 24 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0631 | CAPSULE | 50 mg | ORAL | ANDA | 24 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0632 | CAPSULE | 75 mg | ORAL | ANDA | 24 sections |
CLOMIPRAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7038 | CAPSULE | 25 mg | ORAL | ANDA | 26 sections |
CLOMIPRAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7039 | CAPSULE | 50 mg | ORAL | ANDA | 26 sections |
clomiPRAMINE Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-698 | CAPSULE | 25 mg | ORAL | ANDA | 27 sections |
clomiPRAMINE Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-699 | CAPSULE | 50 mg | ORAL | ANDA | 27 sections |
clomiPRAMINE Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-700 | CAPSULE | 75 mg | ORAL | ANDA | 27 sections |
Clomipramine Hydrochloride | Human Prescription Drug Label | 1 | 16571-683 | CAPSULE | 25 mg | ORAL | ANDA | 23 sections |
Clomipramine Hydrochloride | Human Prescription Drug Label | 1 | 16571-684 | CAPSULE | 50 mg | ORAL | ANDA | 23 sections |
Clomipramine Hydrochloride | Human Prescription Drug Label | 1 | 16571-685 | CAPSULE | 75 mg | ORAL | ANDA | 23 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-849 | CAPSULE | 25 mg | ORAL | ANDA | 21 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-850 | CAPSULE | 50 mg | ORAL | ANDA | 21 sections |
Clomipramine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-851 | CAPSULE | 75 mg | ORAL | ANDA | 21 sections |
Clomipramine hydrochloride | Human Prescription Drug Label | 1 | 27241-210 | CAPSULE | 25 mg | ORAL | ANDA | 23 sections |
Clomipramine hydrochloride | Human Prescription Drug Label | 1 | 27241-211 | CAPSULE | 50 mg | ORAL | ANDA | 23 sections |
Clomipramine hydrochloride | Human Prescription Drug Label | 1 | 27241-212 | CAPSULE | 75 mg | ORAL | ANDA | 23 sections |
CLOMIPRAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-342 | CAPSULE | 25 mg | ORAL | ANDA | 23 sections |
CLOMIPRAMINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-343 | CAPSULE | 50 mg | ORAL | ANDA | 23 sections |